Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New European Vaccine Initiative

Published: Tuesday, November 26, 2013
Last Updated: Tuesday, November 26, 2013
Bookmark and Share
Leading organisations have joined forces to rapidly assess and communicate the benefits and risks of vaccines.

ADVANCE, as the project is called, is in collaboration between European researchers, public health, regulatory agencies and vaccine manufacturers. Karolinska Institutet coordinates the Swedish participation in the project.

The initiative aims to help government agencies and decision-makers in the healthcare field to make quick and well-informed decisions regarding strategies for vaccinating the European population. Such a framework would make it easier for regulators and public health authorities to make fast, more informed decisions regarding vaccination strategies, and help to maintain public confidence in immunisation, particularly when questions are raised about the safety of specific vaccines.

Researchers at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet will participate in the scientific studies that are planned within the ADVANCE project and also contribute their expertise regarding the establishment of the framework. Other Swedish participants include the Swedish Institute for Communicable Disease Control (SMI) and the European Centre for Disease Prevention and Control (ECDC), which has its headquarters in Sweden. Other important partners include the European equivalent of the Swedish Medical Products Agency, EMA, Erasmus University Rotterdam, and several major pharmaceutical companies.

The initiative is funded by the Innovative Medicines Initiative (IMI), which in turn is a collaboration between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA). ADVANCE (Accelerated Development of Vaccine Benefit-risk Collaboration in Europe) receives the equivalent of SEK 95 million in funding over five years. Karolinska Institutet will receive SEK 1.4 million over the same period.

"This collaboration is unique as it is the first time that a European framework is created for evaluating vaccines. It is important that we participate in this project as Sweden has excellent prerequisites, through our health care data register, for evaluating vaccines on a population-based level", says Lisen Arnheim Dahlström, project investigator from Karolinska Institutet.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Possible Goal for New Tuberculosis-Vaccine Identified
A new study shows for the first time the essential role of the molecule SOCS3 in the control of Tuberculosis.
Monday, July 08, 2013
New Hope for Setback-dogged Cancer Treatment
Researchers at Karolinska Institutet announce breakthrough in the study of how IGF-1 receptor-binding antibodies can help those with cancer.
Wednesday, November 28, 2012
Scientific News
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!